期刊文献+

全球抗HIV药物研发进展报告 被引量:2

Report on Progress in Global Research and Development of Anti-HIV Drugs
原文传递
导出
摘要 近年来,艾滋病在世界范围内的迅速传播和蔓延,已严重威胁着人类的健康,且引发了一系列社会问题。报告以Thomson Reuters Cortellis数据库为数据源,从总体研发态势、研发阶段、作用靶点、研究地区、研发机构、销售情况以及交易合作等角度对全球抗HIV药物的研发情况进行多角度、多层次的分析,旨在为我国抗HIV药物的研发提供参考。 The rapid spread of AIDS throughout the world in the past few years poses a serious threat to human health and leads to a series of social problems. Based on Thomson Reuters Cortellis for CI database, the global research and development(RD) of anti-HIV drugs was analyzed in this report from multi-perspectives and multi-levels including overall RD trend, drugs in various development stages, therapeutic targets, research regions and institutions, worldwide sales and deals so as to provide reference for RD of anti-HIV drugs in China.
作者 毕晴
出处 《药学进展》 CAS 2016年第5期389-394,共6页 Progress in Pharmaceutical Sciences
关键词 艾滋病 抗HIV药物 靶点 研发进展 AIDS anti-HIV drugs drug target R&D progress
  • 相关文献

参考文献7

二级参考文献129

  • 1胡玉钦.恩曲他滨的研究现状与应用前景[J].中外医疗,2008,27(20):135-136. 被引量:10
  • 2詹天荣,娄红祥.核苷类抗HIV药物的研究与开发[J].药学进展,2005,29(7):289-295. 被引量:3
  • 3牟英迪,林振广,刘宜辉.抗HIV病毒感染新药——硫酸阿扎那韦[J].齐鲁药事,2007,26(4):253-253. 被引量:3
  • 4Fletcher C V. Enfuvirtide. A new drug for HIV infection [ J]. Lancet, 2003,361 : 1577.
  • 5P F Lin, Wabe B, T Wang, et al. A small molecule HIV-1 inhibitor that targets the H1V-1 envelope and inhibits CD4 receptor binding[J]. Proc Natl Acad Sci USA, 2003,100:11013.
  • 6J M Jacobson, R J Israel, I Lowy, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542 [ J ]. Ant Agent Chem, 2004,48:423.
  • 7Davied A P, Simon G. Initial synthesis of UK-427857 ( maraviroc) [ J ]. Tetrahedon Lett, 2005,46 ( 30 ) :5005.
  • 8Jules Levin. SCH-D, CCR5 receptor inhibitor, new HIV drug in new class of drugs: Anliviral effect, safety, pharmacokinetics, susceptibility[ M]. 11 th Annual Retrocirus Conference, 2004, 2:8.
  • 9Hendrix C W, Collier A C, Lederman M M, et al. Safety pharmacokinctics and antiviral activity of AMD3100, a selective CX- CR4 receptor inhibitorin HIV-1 infection[ J]. J Acquir Immune Deft c Syndr, 2004,37:1253.
  • 10Moyle G, DeJesus E, Boffito M, et al. CXCR4 antagonism: proof of activity with AMD11070 [ C ]. Los Angeles: 14 th Confer ence on Retroviruses and Opportunistic Infection, 2007, (2) :25.

共引文献17

同被引文献9

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部